WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of neurological complications of diabetes, today announced plans to redeem warrants to purchase an aggregate of 1,430,480 shares of common stock, par value $0.0001 per share, that were issued in connection with a NeuroMetrix securities offering in September 2009. The warrants will be redeemed in exchange for 138,763 shares of common stock.
